Study to Evaluate Investigational Allogeneic Cell Therapy Product hOMSC300 for Treatment of Early- to Moderate Stage MSA
Status:
Recruiting
Trial end date:
2026-02-19
Target enrollment:
Participant gender:
Summary
Purpose of this phase 1/2a study is to assess the safety and efficacy of intrathecal
administration of allogeneic human oral mucosa stem cells (hOMSCs) in patients suffering from
early to moderate stage Multiple System Atrophy (MSA) .